Composite Kidney Failure End Points in Contemporary Phase 3 Randomized Controlled Trials of Novel Therapies for IgAN: A Systematic Review and Meta-Analysis Stratified by Mechanism of Action (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0673; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Subgroup analyses were performed stratified by mechanistic class: intestinal/mucosal immunosuppression (targeted-release budesonide, methylprednisolone), complement factor B inhibition (iptacopan), and dual RAAS/endothelin antagonism (sparsentan). Conclusion Contemporary phase 3 IgAN therapies across distinct mechanistic classes consistently reduce composite kidney failure risk by approximately 48% relative to control. Low heterogeneity suggests that the composite KF endpoint captures a shared final common pathway amenable to therapeutic modification regardless of upstream target."
P3 data • Retrospective data • Review • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease • CFB
|